Fennec Pharmaceuticals (TSX:FRX) Beginning Cash Position : C$16.64 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Beginning Cash Position?

Fennec Pharmaceuticals's Beginning Cash Position for the quarter that ended in Dec. 2023 was C$16.64 Mil.

Fennec Pharmaceuticals's quarterly Beginning Cash Position declined from Jun. 2023 (C$24.43 Mil) to Sep. 2023 (C$20.24 Mil) and declined from Sep. 2023 (C$20.24 Mil) to Dec. 2023 (C$16.64 Mil).

Fennec Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2021 (C$38.84 Mil) to Dec. 2022 (C$28.67 Mil) but then increased from Dec. 2022 (C$28.67 Mil) to Dec. 2023 (C$31.90 Mil).

Fennec Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for Fennec Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Beginning Cash Position Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

30.00

17.49

38.84

28.67

31.90

Fennec Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															40.42	32.53	24.43	20.24	16.64

Fennec Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Fennec Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.